AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02879461 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LUMBAR DESCOMPRESSION
Description: ATRODESIS AND DESCOMPRESSIO OFF VERTEBRAL CANAL
Study NCT04564352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Adansonia digitata
Description: Juice of AD fruit
Study NCT02476565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA-Supreme supraglottic device
Description: The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
Study NCT02476565 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel supraglottic device
Description: The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
Study NCT02505516 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Study NCT00600964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX15-070MS
Description: A 60-minute or 3-hour IV infusion every 2-3 weeks.
Study NCT00600964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX15-070MS
Description: GX15-070MS at various doses and schedules
Study NCT02256111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT02256111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Study NCT02256111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Study NCT00659165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Detemir
Description: Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
Study NCT00659165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
Study NCT00124150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate infusion
Description: 80mg per day
Study NCT01764334 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fractional flow reserve
Description: Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014) with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed.
Study NCT01764334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional flow reserve
Description: Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014) with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed.
Study NCT01163734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Intravenous treatment followed oral treatment for 13 days.
Study NCT01163734 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9% and placebo tablet
Description: Intravenous treatment followed by oral treatment for 13 days
Study NCT03748745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH229
Description: tablet, oral, 600 mg once daily for day 1 to day 14
Study NCT03748745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH229
Description: tablet, oral, 600 mg once daily for day 8 to day 14
Study NCT03748745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir dihydrochloride
Description: tablet, oral, 60 mg once daily for day 8 to day 14
Study NCT03748745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir dihydrochloride
Description: tablet, oral, 60 mg once daily for day 1 to day 14
Study NCT04777279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individual physical exercise group
Description: The participants in physical exercise group will receiving individual physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks.
Study NCT04777279 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: individual Branched-Chain Amino Acids supplements group
Description: The participants in nutrition supplements group will receiving Branched-Chain Amino Acids 5 g Branched-Chain Amino Acids every day for 12 weeks.
Study NCT04777279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination of physical exercise and nutrition supplements group
Description: The participants in physical exercise group will receiving physical exercise lead by physiological therapist for 60 minutes/ three times weekly for 12 weeks and 5 g Branched-Chain Amino Acids every day for 12 weeks.
Study NCT00734838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Resolution Microendoscope
Description: Using core biopsy and reduction mammoplasty tissue
Study NCT00734838 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: High Resolution Microendoscope
Description: Using core biopsy and reduction mammoplasty tissue
Study NCT01513772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine(4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
Study NCT01513772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9%
Description: Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
Study NCT00721994 — intervention group
Intervention type: DEVICE
Intervention: Cormet Hip Resurfacing System
Description: Cormet Hip Resurfacing System
Study NCT03923127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elan and HealthDot
Description: Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).
Study NCT01421810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 1 mg PO
Study NCT01421810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhCG
Description: 25 mcg IV
Study NCT01771276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: g-Cath Suture Anchor Delivery Catheter
Description: Evaluate changes in emptying, hormones, satiety and weight loss with use of the g-Cath Suture Anchor Delivery Catheter in maximizing g-Cath Suture Anchor placement to as high as 25 anchors.
Study NCT04400214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Allergy Superheroes Training (FAST) Program
Description: The primary aim of the FAST intervention is to 1) increase the young child's understanding of food allergies (FA) and 2) promote-adherence to FA safety guidelines through active skills training. We will achieve this aim through the use of educational materials (session 1) and a developmentally-tailored skills training intervention (session 2-5). Core components embedded within each skill straining session include instructions, modeling, rehearsal, and reinforcement/corrective feedback. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials (i.e., educational content, skills training components) are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (\<$5 value) at the end of each successfully completed session.
Study NCT04400214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Allergy Knowledge Intervention
Description: The primary aim of the FAK intervention is to increase the young child's understanding of FAs including prevalence, symptoms, and management strategies among other topics. We will achieve this aim through the use of educational materials targeting knowledge acquisition through a variety of didactic materials made freely available through the Food Allergy Research Education (FARE) website (www.foodallergy.org). More specifically, we will employ information embedded within the Food Allergy 101 segment of the FARE website. The young child and their parent/caregiver will be present for the entirety of all sessions; however, all intervention materials are designed with the young child as the primary focal point of interest. All children will be rewarded with a small toy (\<$5 value) at the end of each successfully completed session. All FAK sessions will occur within the child's home and will include informational handouts relevant to the day's session.
Study NCT04172974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth intervention
Description: Modules developed for depression and anxiety based on cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT) and compassion-focused coping
Study NCT02533843 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency catheter ablation
Description: Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)
Study NCT03395535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary Selective Laser Trabeculoplasty Treatment Pathway
Description: Primary Selective Laser Trabeculoplasty Treatment (followed by medications as required) Pathway.~First treatment is SLT, 100 shots of laser over 360 degrees. If this does not reach the target IOP then repeat laser (once only) is given. If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary.
Study NCT03395535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primary Medical Treatment Pathway
Description: Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary.
Study NCT00690547 — intervention group
Intervention type: OTHER
Intervention: muscle activation
Description: activation of the muscle quadriceps femoris
Study NCT01538875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes until high blood pressure is controlled (Maximum number of doses: 3).
Study NCT01538875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
Study NCT00847574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-fat
Description: 35% of calories from fat
Study NCT00847574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower-fat
Description: 20% of calories from fat
Study NCT04334603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training Program
Description: The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital or at home.
Study NCT04334603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training Program
Description: The 12-week exercise-training program will include two sessions of combined exercise training per week, performed at the hospital or at home.
Study NCT02545712 — intervention group
Intervention type: OTHER
Intervention: Exposure to ethanol
Description: The drug source(s) and amount administered daily are noted.
Study NCT02545712 — intervention group
Intervention type: OTHER
Intervention: Exposure to propylene glycol
Description: The drug source(s) and amount administered daily are noted.
Study NCT04172974 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Treatment according to national clinical guideline (referral to GP)
Study NCT02086071 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: re biopsy
Description: re biopsy depending on the location of the pathology
Study NCT04324112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: Binimetinib will be given orally at a dose of 45mg BID continuously for 28-day cycles with no resting period between cycles.
Study NCT04324112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Encorafenib will be given orally at a dose of 450mg QD continuously for 28-day cycles with no resting period between cycles.
Study NCT04434235 — intervention group
Intervention type: OTHER
Intervention: axial load
Description: With a helmet with Velcro fastener we will add additional weight to produce axial load on the cervical spine
Study NCT03022318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbidopa-levodopa 25-100 mg tablets
Description: See arm/group descriptions
Study NCT03299218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SNF (Wawamum)
Description: A monthly ration of 30 sachets of SNF (one 50 gram sachet of Wawamum per child per day) will be provided by LHWs. Each recruited child will receive SNF on a monthly basis for the duration of 18 months during his/her age of 6-24 months.
Study NCT03299218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social and behaviour change communication (SBCC)
Description: SBCC messages will be delivered by LHWs in their monthly routine household visits. Male and female group sessions will be arranged on quarterly basis with the help of health committees.
Study NCT03299218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash
Description: Cash totaling 1600 rupees per month will be transferred by BISP throughout the study period.
Study NCT02525146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ARTAS (Antiretroviral Treatment and Access to Services) intervention
Study NCT00263393 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin
Description: The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.
Study NCT00263393 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Promotion
Description: The second intervention was a health promotion program designed to increase knowledge of cardiovascular risk factors compared to continued usual practices.
Study NCT02507271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Fitness Program
Description: This intervention involves work on a computer by responding to sounds for five hours a week, approximately one hour a day five days a week at the Rusk Institute for Rehabilitation.
Study NCT02507271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Weekly Telephone Contact
Description: This intervention involves weekly telephone calls over a period of approximately 8 weeks to inquire about the participant's involvement in cognitively stimulating activities (such as reading, working on the computer, puzzles, etc.)
Study NCT02015286 — intervention group
Intervention type: DEVICE
Intervention: easypod™
Description: Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
Study NCT01861600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S-26 Gold
Description: (13.4 g/L protein) with 100% Fat Blend A
Study NCT01861600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-26 Gold EF1
Description: (13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend
Study NCT01861600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-26 Gold EF2
Description: (13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 3.0 g/L oligofructose
Study NCT01861600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-26 Gold EF3
Description: (13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 5.0 g/L oligofructose
Study NCT01861600 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Human Milk
Description: Human Milk
Study NCT02145000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine (BRV-PV)
Description: Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9, or placebo, will be administered at 4 week intervals between doses (with a window of -1 to +4 weeks). The first administration will occur at 6-8 weeks of age.
Study NCT02145000 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05395702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-Gamma
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study NCT02099331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Study NCT02099331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Melatonin)
Description: Sugar pill manufactured to mimic Melatonin 20 mg
Study NCT02545712 — intervention group
Intervention type: OTHER
Intervention: Exposure to benzyl alcohol
Description: The drug source(s) and amount administered daily are noted.
Study NCT02545712 — intervention group
Intervention type: OTHER
Intervention: Exposure to acesulfam potassium
Description: The drug source(s) and amount administered daily are noted.
Study NCT02545712 — intervention group
Intervention type: OTHER
Intervention: Exposure to aspartame
Description: The drug source(s) and amount administered daily are noted.
Study NCT02545712 — intervention group
Intervention type: OTHER
Intervention: Exposure to glycerol
Description: The drug source(s) and amount administered daily are noted.
Study NCT02545712 — intervention group
Intervention type: OTHER
Intervention: Exposure to sorbitol
Description: The drug source(s) and amount administered daily are noted.
Study NCT02545712 — intervention group
Intervention type: OTHER
Intervention: Exposure to methyl-p-hydroxybenzoate
Description: The drug source(s) and amount administered daily are noted.
Study NCT02545712 — intervention group
Intervention type: OTHER
Intervention: Exposure to propanyl-p-hydroxybenzoate
Description: The drug source(s) and amount administered daily are noted.
Study NCT02545712 — intervention group
Intervention type: OTHER
Intervention: Exposure to polysorbate-80
Description: The drug source(s) and amount administered daily are noted.
Study NCT04335994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: In-laboratory polysomnography
Description: Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
Study NCT04335994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Sleep Apnea Test
Description: Use of a home sleep apnea test that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
Study NCT02065128 — intervention group
Intervention type: OTHER
Intervention: Capsaicin cough challenge test
Description: The capsaicin cough challenge testing will be conducted in the pulmonary function laboratory at SMH by a pulmonary function technologist. The test involves having the participant inhale increasing concentrations of capsaicin solutions and assessing their response. The tidal breathing method and solution preparation presented by Nejla, et al. 12 will be used to conduct this testing. The tidal breathing method is preferred to the alternative dosimeter method as it produces similar results with lower capsaicin concentrations thereby resulting in less throat irritation for the participant. The technique is detailed in the following sections.
Study NCT00045396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT02487979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glembatumumab Vedotin
Description: Given IV
Study NCT02487979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02710630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate tablet E1